GenAssist Therapeutics
company
About
GenAssist Therapeutics develops gene therapy drugs using base editing technology, which is advantageous in the field of DMD treatment.
- 1 - 10
Highlights
Details
- Last Funding Type
- Series A
- Industries
- Biotechnology,Health Care,Medical,Therapeutics
- Founded date
- Jan 1, 2020
- Number Of Employee
- 1 - 10
- Operating Status
- Active
GenAssist Therapeutics develops gene therapy drugs using base editing technology, which is advantageous in the field of DMD treatment. Founded in 2020, GenAssist was founded by outstanding scientists and industry experts in July 2020. They are committed to the development of gene editing drugs for a variety of genetic diseases.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
—
GenAssist Therapeutics has raised a total of
—
in funding over 2 rounds. Their latest funding was raised on
Dec 8, 2022 from a Series A round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Dec 8, 2022 | Series A | — | 1 |
AstraZeneca
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
1
1
GenAssist Therapeutics is funded by 1 investors.
AstraZeneca
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
AstraZeneca
|
Yes | Series A |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
